Yiqun Gu
Research Subjects
Yiqun Gu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Xinghai Wang
Jiangsu Family Planning Research Institute (X.W.), Nanjing 210036, China
2 shared publicationsChengliang Xiong
Family Planning Research Institute (C.X.), Tongji Medical College, Wuhan 430030, China
1 shared publicationDingzhi Ma
1 shared publicationDong Yuan
1 shared publicationJiansun Tong
1 shared publicationKangshou Yao
Zhejiang Institute of Planned Parenthood (K.Y.), Hangzhou 310012, China
1 shared publication
Latest Publications
- Open Access
- 14 June 2010
- Published by Medknow in Asian Journal of Andrology
- Vol. 12 (4) , 605-606
Insights into semen analysis: a Chinese perspective on the fifth edition of the WHO laboratory manual for the examination and processing of human semen
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 14 June 2010
- Published by Medknow in Asian Journal of Andrology
- Vol. 12 (4) , 605-606
Open AccessInsights into semen analysis: a Chinese perspective on the fifth edition of the WHO laboratory manual for the examination and processing of human semen
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- Open Access
- 1 June 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (6) , 1910-1915
Multicenter Contraceptive Efficacy Trial of Injectable Testosterone Undecanoate in Chinese Men
Context: Hormonal male contraceptive regimens effectively and reversibly suppress sperm production, but there are few large-scale efficacy studies. Objective: The safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive was assessed. Design: This was a multicenter, phase III, contraceptive efficacy clinical trial. Participants: A total of 1045 healthy fertile Chinese men were recruited throughout China into the study. Intervention(s): Injections of 500 mg TU were administered monthly for 30 months. A definition of severe oligozoospermia (≤1 × 106/ml) was used as a criterion of spermatogenic suppression and as the threshold for entering the contraceptive efficacy phase. Main Outcome Measure(s): The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests. Results: Forty-three participants (4.8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1554.1 person-years of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1.1 per 100 men. The combined method failure rate was 6.1%, comprising 4.8% with inadequate suppression and 1.3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants. Conclusions: Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.
- 1 June 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (6) , 1910-1915
Open AccessMulticenter Contraceptive Efficacy Trial of Injectable Testosterone Undecanoate in Chinese Men
Context: Hormonal male contraceptive regimens effectively and reversibly suppress sperm production, but there are few large-scale efficacy studies. Objective: The safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive was assessed. Design: This was a multicenter, phase III, contraceptive efficacy clinical trial. Participants: A total of 1045 healthy fertile Chinese men were recruited throughout China into the study. Intervention(s): Injections of 500 mg TU were administered monthly for 30 months. A definition of severe oligozoospermia (≤1 × 106/ml) was used as a criterion of spermatogenic suppression and as the threshold for entering the contraceptive efficacy phase. Main Outcome Measure(s): The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests. Results: Forty-three participants (4.8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1554.1 person-years of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1.1 per 100 men. The combined method failure rate was 6.1%, comprising 4.8% with inadequate suppression and 1.3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants. Conclusions: Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.
- 1 August 2004
- Vol. 10 (8) , 572-7, 581
[Effect of injection of testosterone undecanoate and depot medroxyprogesterone acetate on the suppression of spermatogenesis].
To observe depot medroxyprogesterone acetate (DMPA) and testosterone undecanoate (TU) injected at 8-week intervals for the suppression of spermatogenesis in healthy Chinese men. After screening, 30 healthy volunteers were enrolled and randomly assigned to 3 dosage-groups (n = 10/group): 1000 mg TU (Group A), 1000 mg TU plus 150 mg DMPA (Group B), 1000 mg TU plus 300 mg DMPA (Group C). All dosages were given as intramuscular injections at 8-week intervals. The study consisted of an 8-week control (baseline) period, a 24-week treatment period and a 24-week recovery period. Consistent azoospermia or severe oligozoospermia was achieved and maintained in all the volunteers during the treatment period, except 2 in the mere TU group who experienced a "rebound" in sperm concentrations. An 8-week regimen of TU plus DMPA at both tested combination dosages effectively suppressed spermatogenesis to azoospermia. All volunteers tolerated the injections; no serious adverse effects were reported. The lower combined dosage is recommended for further testing in an expanded clinical trial or contraceptive efficacy study.
- 1 August 2004
- Vol. 10 (8) , 572-7, 581
[Effect of injection of testosterone undecanoate and depot medroxyprogesterone acetate on the suppression of spermatogenesis].
To observe depot medroxyprogesterone acetate (DMPA) and testosterone undecanoate (TU) injected at 8-week intervals for the suppression of spermatogenesis in healthy Chinese men. After screening, 30 healthy volunteers were enrolled and randomly assigned to 3 dosage-groups (n = 10/group): 1000 mg TU (Group A), 1000 mg TU plus 150 mg DMPA (Group B), 1000 mg TU plus 300 mg DMPA (Group C). All dosages were given as intramuscular injections at 8-week intervals. The study consisted of an 8-week control (baseline) period, a 24-week treatment period and a 24-week recovery period. Consistent azoospermia or severe oligozoospermia was achieved and maintained in all the volunteers during the treatment period, except 2 in the mere TU group who experienced a "rebound" in sperm concentrations. An 8-week regimen of TU plus DMPA at both tested combination dosages effectively suppressed spermatogenesis to azoospermia. All volunteers tolerated the injections; no serious adverse effects were reported. The lower combined dosage is recommended for further testing in an expanded clinical trial or contraceptive efficacy study.